Arcus Biosciences Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
10.3%projected annual EPS growth
Analyst Coverage
12analysts covering
FY Revenue (est.)
$75.7Mnext fiscal year
FY EPS (est.)
-$3.65next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Presentation of mature ORR and initial PFS data for casdatifan plus cabozantinib cohort | 31 Dec 2026 |
| Presentation of initial data from early-line ARC-20 cohorts (casdatifan plus zimberelimab in 1L ccRCC) | 31 Dec 2026 |
Monitoring Framework
Key Performance Indicators
Cash, Cash Equivalents and Marketable Securities Quarterly876MTarget: Cash runway until at least the second half of 2028
Casdatifan Confirmed Objective Response Rate (cORR) in 100mg QD late-line monotherapy45.0%
Casdatifan Median Progression-Free Survival (mPFS) in late-line ccRCC15.1Target: Outperform belzutifan benchmark of 5.6 months
Watch Items
- Phase 3 PEAK-1 trial enrollment completionTrigger: Enrollment completion expected by year-end 2026
- Initiation of Phase 3 first-line (1L) ccRCC trial for casdatifanTrigger: Initiation of 1L Phase 3 study expected by year-end 2026
- Gilead collaboration option rights transitionTrigger: Expiration of broad option rights on July 14, 2026Action: Manage transition to time-limited options on specific assets (AB801, AB598, AB102, and TNF inhibitor).
Research as of 19 Jun 2026